KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Depreciation & Amortization (CF) (2016 - 2025)

NovoCure (NVCR) has disclosed Depreciation & Amortization (CF) for 12 consecutive years, with $4.2 million as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) rose 35.89% to $4.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.6 million through Dec 2025, up 30.4% year-over-year, with the annual reading at $14.6 million for FY2025, 30.4% up from the prior year.
  • Depreciation & Amortization (CF) hit $4.2 million in Q4 2025 for NovoCure, up from $3.7 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $4.2 million in Q4 2025 to a low of $2.4 million in Q1 2021.
  • Historically, Depreciation & Amortization (CF) has averaged $2.9 million across 5 years, with a median of $2.7 million in 2023.
  • Biggest five-year swings in Depreciation & Amortization (CF): dropped 12.31% in 2024 and later surged 49.02% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $2.7 million in 2021, then increased by 1.24% to $2.7 million in 2022, then rose by 0.85% to $2.7 million in 2023, then grew by 13.99% to $3.1 million in 2024, then soared by 35.89% to $4.2 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for NVCR at $4.2 million in Q4 2025, $3.7 million in Q3 2025, and $3.4 million in Q2 2025.